Difference between revisions of "Team:NCTU Formosa/Composite Part"

 
(46 intermediate revisions by 4 users not shown)
Line 10: Line 10:
 
a, abbr, acronym, address, big, cite, code,
 
a, abbr, acronym, address, big, cite, code,
 
del, dfn, em, font, img, ins, kbd, q, s, samp,
 
del, dfn, em, font, img, ins, kbd, q, s, samp,
−
small, strike, strong, sub, sup, tt, var,
+
small, strike, strong, tt, var,
 
b, u, i, center,
 
b, u, i, center,
 
dl, dt, dd, ol, ul, li,
 
dl, dt, dd, ol, ul, li,
Line 57: Line 57:
 
}
 
}
 
.p01{
 
.p01{
−
background-color:#1599EA;
+
background-color:#FF6347;
 
position:relative;
 
position:relative;
 
height:70vh;
 
height:70vh;
 
width:100%;
 
width:100%;
 
left:0vw;
 
left:0vw;
 +
opacity:0.8;
 
}
 
}
 
.p02{
 
.p02{
Line 69: Line 70:
 
}
 
}
 
.background1{
 
.background1{
−
background-image:url("https://static.igem.org/mediawiki/2015/9/97/NCTU_Formosa_Composite_Part_logo.png");
+
background-image:url("https://static.igem.org/mediawiki/2015/d/dd/NCTU_Formosa_E.cotector4.png");
 
background-repeat:no-repeat;
 
background-repeat:no-repeat;
−
background-position:center;
+
background-position:center 12vh;
 
position:relative;
 
position:relative;
 
height:70vh;
 
height:70vh;
 
width:40vw;
 
width:40vw;
−
background-size:70%;
+
background-size:55%;
 
top:0vh;
 
top:0vh;
 
left:10vw;
 
left:10vw;
Line 86: Line 87:
 
position:relative;
 
position:relative;
 
right:20vw;
 
right:20vw;
−
top:20vh;
+
top:33vh;
 
color:#fff;
 
color:#fff;
 
z-index:100;
 
z-index:100;
Line 92: Line 93:
 
text-align:center;
 
text-align:center;
 
}
 
}
−
 
 
.content{
 
.content{
 
font-family:Arial;
 
font-family:Arial;
Line 162: Line 162:
 
text-decoration:none;
 
text-decoration:none;
 
}
 
}
−
span{font-size:18pt;}
+
.part span{font-size:18pt;}
 +
.reference{
 +
font-size:10pt;
 +
position:relative;
 +
border-top:#999 1px solid;
 +
}
 +
 
  
 +
#groupparts {
 +
margin: 0 auto;
 +
background-color:#FCFCDE;}
 
</style>
 
</style>
  
Line 173: Line 182:
 
</div>
 
</div>
 
<div class="p02">
 
<div class="p02">
−
<div class="content"></div>
+
<div class="content">
 
<h2>Composite Part</h2>
 
<h2>Composite Part</h2>
  
Line 185: Line 194:
 
                       <span><a href="http://parts.igem.org/Part:BBa_K1694015">BBa_K1694015</a></span><br>
 
                       <span><a href="http://parts.igem.org/Part:BBa_K1694015">BBa_K1694015</a></span><br>
 
                                 OmpA-anti-HER2<br>
 
                                 OmpA-anti-HER2<br>
−
</td><td></td><td>In order to change the scFv parts easily, we added a NcoI restriction site between OmpA and scFv so that we can <B>change various scFv DNA sequence</B> using the NcoI restriction enzyme.</td></tr>  
+
</td><td></td><td>In order to change the scFv parts easily, we added a <i>Nco</i>I restriction site between OmpA and scFv so that we can change various scFv DNA sequence using the <i>Nco</i>I restriction enzyme.</td></tr>  
  
 
<tr><td class="part"><span><a href="http://parts.igem.org/Part:BBa_K1694023">BBa_K1694023</a></span><br>
 
<tr><td class="part"><span><a href="http://parts.igem.org/Part:BBa_K1694023">BBa_K1694023</a></span><br>
−
                                   Pcons+RBS+OmpA-anti-VEGF<br>
+
                                   P<sub>cons</sub>+RBS+OmpA-anti-VEGF<br>
 
                       <span><a href="http://parts.igem.org/Part:BBa_K1694024">BBa_K1694024</a></span><br>
 
                       <span><a href="http://parts.igem.org/Part:BBa_K1694024">BBa_K1694024</a></span><br>
−
                                 Pcons+RBS+OmpA-anti-EGFR<br>
+
                                 P<sub>cons</sub>+RBS+OmpA-anti-EGFR<br>
 
                       <span><a href="http://parts.igem.org/Part:BBa_K1694025">BBa_K1694025</a></span><br>
 
                       <span><a href="http://parts.igem.org/Part:BBa_K1694025">BBa_K1694025</a></span><br>
−
                                 Pcons+RBS+OmpA-anti-HER2<br>
+
                                 P<sub>cons</sub>+RBS+OmpA-anti-HER2<br>
−
</td><td></td><td>By ligating the constitutive promoter (BBa_J23101), strong ribosome binding site (BBa_B0034) and Lpp-OmpA-scFv, we were able to display scFv on the <i>E.coli</i> outer membrane continuously.  
+
</td><td></td><td>By ligating the constitutive promoter (<a href="http://parts.igem.org/Part:BBa_J23101">BBa_J23101</a>), strong ribosome binding site (<a href="http://parts.igem.org/Part:BBa_B0034">BBa_B0034</a>) and Lpp-OmpA-scFv, we were able to display scFv on the <i>E.coli</i> outer membrane continuously.  
 
Having this part, we can co-transform with other parts in order to produce color as the detection signal.<br><br>
 
Having this part, we can co-transform with other parts in order to produce color as the detection signal.<br><br>
  
−
In addition, by co-transforming these different types of <i>E.coli</i> with different fluorescence or color as signals, we are able to create a platform which can detect <B>multimarker</B> and consequently achieve combination therapy.
+
In addition, by co-transforming these different types of <i>E.coli</i> with different fluorescence or color as signals, we are able to create a platform which can detect multimarker and consequently achieve combination therapy.
 
</td></tr>  
 
</td></tr>  
  
 
<tr><td class="part"><span><a href="http://parts.igem.org/Part:BBa_K1694033">BBa_K1694033</a></span><br>
 
<tr><td class="part"><span><a href="http://parts.igem.org/Part:BBa_K1694033">BBa_K1694033</a></span><br>
−
                                   Pcons+RBS+OmpA-anti-VEGF+RBS+GFP+Ter<br>
+
                                   P<sub>cons</sub>+RBS+OmpA-anti-VEGF+RBS+GFP+Ter<br>
 
                       <span><a href="http://parts.igem.org/Part:BBa_K1694034">BBa_K1694034</a></span><br>
 
                       <span><a href="http://parts.igem.org/Part:BBa_K1694034">BBa_K1694034</a></span><br>
−
                                 Pcons+RBS+OmpA-anti-EGFR+RBS+GFP+Ter<br>
+
                                 P<sub>cons</sub>+RBS+OmpA-anti-EGFR+RBS+GFP+Ter<br>
 
                       <span><a href="http://parts.igem.org/Part:BBa_K1694035">BBa_K1694035</a></span><br>
 
                       <span><a href="http://parts.igem.org/Part:BBa_K1694035">BBa_K1694035</a></span><br>
−
                                 Pcons+RBS+OmpA-anti-HER2+RBS+GFP+Ter<br>
+
                                 P<sub>cons</sub>+RBS+OmpA-anti-HER2+RBS+GFP+Ter<br>
 
                       <span><a href="http://parts.igem.org/Part:BBa_K1694044">BBa_K1694044</a></span><br>
 
                       <span><a href="http://parts.igem.org/Part:BBa_K1694044">BBa_K1694044</a></span><br>
 
                       Pcons+RBS+OmpA-anti-EGFR+RBS+RFP+Ter<br>
 
                       Pcons+RBS+OmpA-anti-EGFR+RBS+RFP+Ter<br>
 
                       <span><a href="http://parts.igem.org/Part:BBa_K1694045">BBa_K1694045</a></span><br>
 
                       <span><a href="http://parts.igem.org/Part:BBa_K1694045">BBa_K1694045</a></span><br>
−
                                 Pcons+RBS+OmpA-anti-HER2+RBS+BFP+Ter<br>
+
                                 P<sub>cons</sub>+RBS+OmpA-anti-HER2+RBS+BFP+Ter<br>
 
                                  
 
                                  
 
</td><td></td><td>The most commonly constructing way of composite parts is to ligate the required parts together. We also provide this kind of parts.<br>
 
</td><td></td><td>The most commonly constructing way of composite parts is to ligate the required parts together. We also provide this kind of parts.<br>
−
At the back of the Lpp-OmpA-scFv part, we ligated the weaker ribosome biding site (BBa_B0030), different fluorescent protein and terminator (BBa_J61048) to make it continuously and simultaneously express the fluorescence and the scFv . We used a weak ribosome binding site to ensure that scFv's production will not be affected.  
+
At the back of the Lpp-OmpA-scFv part, we ligated the weaker ribosome biding site (<a href="網址">BBa_B0030</a>), different fluorescent protein and terminator (<a href="http://parts.igem.org/Part:BBa_J61048">BBa_J61048</a>) to make it continuously and simultaneously express the fluorescence and the scFv. We used a weak ribosome binding site to ensure that scFv's production will not be affected.  
 
</td></tr>  
 
</td></tr>  
  
 
<tr><td class="part"><span><a href="http://parts.igem.org/Part:BBa_K1694053">BBa_K1694053</a></span><br>
 
<tr><td class="part"><span><a href="http://parts.igem.org/Part:BBa_K1694053">BBa_K1694053</a></span><br>
−
                                   Pcons+RBS+OmpA-anti-VEGF+RBS+amilCP+Ter<br>
+
                                   P<sub>cons</sub>+RBS+OmpA-anti-VEGF+RBS+amilCP+Ter<br>
 
                       <span><a href="http://parts.igem.org/Part:BBa_K1694054">BBa_K1694054</a></span><br>
 
                       <span><a href="http://parts.igem.org/Part:BBa_K1694054">BBa_K1694054</a></span><br>
−
                                 Pcons+RBS+OmpA-anti-EGFR+RBS+amilCP+Ter<br>
+
                                 P<sub>cons</sub>+RBS+OmpA-anti-EGFR+RBS+amilCP+Ter<br>
−
                       <span><a href="http://parts.igem.org/Part:BBa_K1694055">BBa_K1694035</a></span><br>
+
                       <span><a href="http://parts.igem.org/Part:BBa_K1694055">BBa_K1694055</a></span><br>
−
                                 Pcons+RBS+OmpA-anti-HER2+RBS+amilCP+Ter<br>
+
                                 P<sub>cons</sub>+RBS+OmpA-anti-HER2+RBS+amilCP+Ter<br>
 
</td><td></td><td>Chromoprotein is another example of what can be added when making your own probe.<br>
 
</td><td></td><td>Chromoprotein is another example of what can be added when making your own probe.<br>
−
We constructed this part as the Pcons+RBS+OmpA-scFv+RBS+fluorescent protein+Terminator part.
+
We constructed this part as the P<sub>cons</sub>+RBS+OmpA-scFv+RBS+fluorescent protein+Terminator part.
 
</td></tr>  
 
</td></tr>  
  
 
<tr><td class="part"><span><a href="http://parts.igem.org/Part:BBa_K1694027">BBa_K1694027</a></span><br>
 
<tr><td class="part"><span><a href="http://parts.igem.org/Part:BBa_K1694027">BBa_K1694027</a></span><br>
−
                                   Pinduce+RBS+FadL-GBP<br>  
+
                                   P<sub>cons</sub>+RBS+FadL-GBP<br>  
−
</td><td></td><td>By ligating the induced promoter (BBa_R0010), ribosome binding site (BBa_B0034), FadL-GBP and terminator (BBa_J61048), we can continuously display the GBP on the <i>E.coli</i> outer membrane.<br>
+
</td><td></td><td>By ligating the induced promoter (<a href="http://parts.igem.org/Part:BBa_J23110">BBa_J23110</a>), ribosome binding site (<a href="http://parts.igem.org/Part:BBa_B0034">BBa_B0034</a>) and FadL-GBP, we can continuously display the GBP on the <i>E.coli</i> outer membrane.<br>
 
Then we co-transform the OmpA-scFv parts and this FadL-GBP parts into the same <i>E.coli</i>, hence allowing our <i>E.coli</i> to bind on gold chips and detect antigens simultaneously.  
 
Then we co-transform the OmpA-scFv parts and this FadL-GBP parts into the same <i>E.coli</i>, hence allowing our <i>E.coli</i> to bind on gold chips and detect antigens simultaneously.  
 
</td></tr>  
 
</td></tr>  
  
 
<tr><td class="part"><span><a href="http://parts.igem.org/Part:BBa_K1694037">BBa_K1694037</a></span><br>
 
<tr><td class="part"><span><a href="http://parts.igem.org/Part:BBa_K1694037">BBa_K1694037</a></span><br>
−
                                 Pinduce+RBS+FadL-GBP+RBS+GFP+Ter<br>  
+
                                 P<sub>cons</sub>+RBS+FadL-GBP+RBS+GFP+Ter<br>  
−
</td><td></td><td>With this part, we can testt the GBP function by observing the green fluorescence on the gold chip.  
+
</td><td></td><td>With this part, we can test the GBP function by observing the green fluorescence on the gold chip. Terminator  is (<a href="http://parts.igem.org/Part:BBa_B0015">BBa_B0015</a>).
 
</td></tr>  
 
</td></tr>  
  
Line 238: Line 247:
 
</div>
 
</div>
  
−
<div class="content">
 
−
<div class="reference">
 
−
<b>Reference<br></b>
 
−
[1] C Hartmann et al. (2010) Peptide mimotopes recognized by antibodies cetuximab and matuzumab induce a functionally equivalent anti-EGFR immune response http://www.nature.com/onc/journal/v29/n32/pdf/onc2010195a.pdf<br>
 
−
[2] DrugBank: Bevacizumab (DB00112) http://www.drugbank.ca/drugs/DB00112<br>
 
−
[3] DrugBank: Cetuximab (DB00002) http://www.drugbank.ca/drugs/DB00002<br>
 
−
[4] DrugBank: Trastuzumab (DB00072) http://www.drugbank.ca/drugs/DB00072<br>
 
−
[5] Tae Jung Park et al. (2009) Development of a whole-cell biosensor by cell surface display of a gold-binding polypeptide on the gold surface<br>
 
 
</div>
 
</div>
 +
<div class="goto" style="background-color:#FCFCDE;">
 +
<a href="https://2015.igem.org/Team:NCTU_Formosa/Project"><img src="https://static.igem.org/mediawiki/2015/3/3c/%E7%AE%AD%E9%A0%AD1.png"; width=50vw;><br><br>Back to Navigation</a>
 +
</div>
 +
<div class="goto1" style="background-color:#FCFCDE;">
 +
<a href="https://2015.igem.org/Team:NCTU_Formosa/Practices"><img src="https://static.igem.org/mediawiki/2015/c/c2/%E7%AE%AD%E9%A0%AD2.png"; width=50vw;><br><br>Go to Practices</a>
 
</div>
 
</div>
  
−
 
−
<div class="goto">
 
−
<a href="https://2015.igem.org/Team:NCTU_Formosa/Project"><img src="https://static.igem.org/mediawiki/2015/3/3c/%E7%AE%AD%E9%A0%AD1.png"; width=50vw;><br><br>Back to project</a>
 
−
</div>
 
−
<div class="goto1">
 
−
<a href="https://2015.igem.org/Team:NCTU_Formosa/Part_Collection"><img src="https://static.igem.org/mediawiki/2015/c/c2/%E7%AE%AD%E9%A0%AD2.png"; width=50vw;><br><br>Go to Part Collection</a>
 
−
</div>
 
−
</div>
 
 
</body>
 
</body>
 
</html>
 
</html>
 +
 
{{Team:NCTU_Formosa/footer}}
 
{{Team:NCTU_Formosa/footer}}

Latest revision as of 03:58, 19 September 2015

Composite Parts

Composite Part

BBa_K1694013
OmpA-anti-VEGF
BBa_K1694014
OmpA-anti-EGFR
BBa_K1694015
OmpA-anti-HER2
In order to change the scFv parts easily, we added a NcoI restriction site between OmpA and scFv so that we can change various scFv DNA sequence using the NcoI restriction enzyme.
BBa_K1694023
Pcons+RBS+OmpA-anti-VEGF
BBa_K1694024
Pcons+RBS+OmpA-anti-EGFR
BBa_K1694025
Pcons+RBS+OmpA-anti-HER2
By ligating the constitutive promoter (BBa_J23101), strong ribosome binding site (BBa_B0034) and Lpp-OmpA-scFv, we were able to display scFv on the E.coli outer membrane continuously. Having this part, we can co-transform with other parts in order to produce color as the detection signal.

In addition, by co-transforming these different types of E.coli with different fluorescence or color as signals, we are able to create a platform which can detect multimarker and consequently achieve combination therapy.
BBa_K1694033
Pcons+RBS+OmpA-anti-VEGF+RBS+GFP+Ter
BBa_K1694034
Pcons+RBS+OmpA-anti-EGFR+RBS+GFP+Ter
BBa_K1694035
Pcons+RBS+OmpA-anti-HER2+RBS+GFP+Ter
BBa_K1694044
Pcons+RBS+OmpA-anti-EGFR+RBS+RFP+Ter
BBa_K1694045
Pcons+RBS+OmpA-anti-HER2+RBS+BFP+Ter
The most commonly constructing way of composite parts is to ligate the required parts together. We also provide this kind of parts.
At the back of the Lpp-OmpA-scFv part, we ligated the weaker ribosome biding site (BBa_B0030), different fluorescent protein and terminator (BBa_J61048) to make it continuously and simultaneously express the fluorescence and the scFv. We used a weak ribosome binding site to ensure that scFv's production will not be affected.
BBa_K1694053
Pcons+RBS+OmpA-anti-VEGF+RBS+amilCP+Ter
BBa_K1694054
Pcons+RBS+OmpA-anti-EGFR+RBS+amilCP+Ter
BBa_K1694055
Pcons+RBS+OmpA-anti-HER2+RBS+amilCP+Ter
Chromoprotein is another example of what can be added when making your own probe.
We constructed this part as the Pcons+RBS+OmpA-scFv+RBS+fluorescent protein+Terminator part.
BBa_K1694027
Pcons+RBS+FadL-GBP
By ligating the induced promoter (BBa_J23110), ribosome binding site (BBa_B0034) and FadL-GBP, we can continuously display the GBP on the E.coli outer membrane.
Then we co-transform the OmpA-scFv parts and this FadL-GBP parts into the same E.coli, hence allowing our E.coli to bind on gold chips and detect antigens simultaneously.
BBa_K1694037
Pcons+RBS+FadL-GBP+RBS+GFP+Ter
With this part, we can test the GBP function by observing the green fluorescence on the gold chip. Terminator is (BBa_B0015).


Back to Navigation


Go to Practices